X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9519) 9519
Newsletter (63) 63
Magazine Article (14) 14
Book Chapter (12) 12
Conference Proceeding (3) 3
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8232) 8232
male (4724) 4724
female (4238) 4238
pyrimidines - therapeutic use (4204) 4204
pyrimidines - adverse effects (3869) 3869
middle aged (3438) 3438
adult (2928) 2928
aged (2523) 2523
pyrimidines - administration & dosage (2276) 2276
imatinib mesylate (2210) 2210
oncology (2137) 2137
treatment outcome (1900) 1900
animals (1829) 1829
benzamides (1746) 1746
pharmacology & pharmacy (1558) 1558
pyrimidines - pharmacology (1530) 1530
antineoplastic agents - therapeutic use (1392) 1392
piperazines - therapeutic use (1362) 1362
piperazines - adverse effects (1267) 1267
antineoplastic agents - adverse effects (1255) 1255
hematology (1181) 1181
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1170) 1170
cancer (1045) 1045
protein kinase inhibitors - therapeutic use (962) 962
care and treatment (927) 927
pyrimidines (877) 877
therapy (864) 864
imatinib (853) 853
adolescent (848) 848
drug therapy (836) 836
pyrimidines - pharmacokinetics (823) 823
protein kinase inhibitors - adverse effects (822) 822
dose-response relationship, drug (816) 816
aged, 80 and over (814) 814
research (810) 810
sulfonamides - therapeutic use (793) 793
young adult (769) 769
voriconazole (738) 738
analysis (730) 730
rosuvastatin calcium (723) 723
mice (712) 712
medicine & public health (697) 697
sulfonamides - adverse effects (648) 648
safety (646) 646
chronic myelogenous leukemia (624) 624
piperazines - administration & dosage (624) 624
efficacy (619) 619
protein-tyrosine kinases - antagonists & inhibitors (614) 614
pharmacokinetics (603) 603
chronic myeloid-leukemia (580) 580
antineoplastic agents - administration & dosage (573) 573
dasatinib (564) 564
chemotherapy (563) 563
double-blind method (544) 544
chronic myeloid leukemia (539) 539
ultraviolet rays - adverse effects (538) 538
time factors (536) 536
abridged index medicus (516) 516
risk factors (513) 513
clinical trials (509) 509
leukemia (509) 509
health aspects (499) 499
medicine, general & internal (487) 487
antineoplastic combined chemotherapy protocols - therapeutic use (480) 480
rats (469) 469
administration, oral (467) 467
drug administration schedule (467) 467
clinical trials as topic (465) 465
triazoles - therapeutic use (463) 463
antifungal agents - therapeutic use (434) 434
sulfonamides - administration & dosage (434) 434
follow-up studies (433) 433
pyrroles - therapeutic use (433) 433
fluorobenzenes - therapeutic use (431) 431
mutation (431) 431
biochemistry & molecular biology (428) 428
dosage and administration (424) 424
antineoplastic agents (423) 423
protein kinase inhibitors - administration & dosage (422) 422
dermatology (419) 419
disease-free survival (413) 413
retrospective studies (411) 411
drug therapy, combination (407) 407
drug interactions (404) 404
internal medicine (402) 402
antimitotic agents (386) 386
dna damage (384) 384
double-blind (383) 383
tyrosine kinase inhibitor (378) 378
hematology, oncology and palliative medicine (376) 376
rosuvastatin (374) 374
child (368) 368
patients (366) 366
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (362) 362
triazoles - adverse effects (359) 359
pharmacology/toxicology (351) 351
tumors (350) 350
pyrazoles - therapeutic use (346) 346
prognosis (341) 341
expression (337) 337
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9208) 9208
Japanese (136) 136
German (119) 119
French (100) 100
Spanish (51) 51
Chinese (38) 38
Russian (26) 26
Portuguese (13) 13
Italian (12) 12
Hungarian (10) 10
Danish (8) 8
Dutch (8) 8
Czech (5) 5
Polish (5) 5
Swedish (5) 5
Norwegian (4) 4
Turkish (3) 3
Croatian (2) 2
Hebrew (2) 2
Finnish (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2016, Volume 56, Issue 3, pp. kew442 - 425
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
...REVIEWS Neurological adverse effects caused by cytotoxic and targeted therapies David Schiff, Patrick Y. Wen and Martin J. van den Bent Abstract | Historically... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article